News
PAVMW
0.0290
-3.33%
-0.0010
PAVMED INC <PAVM.O>: ASCENDIANT CAPITAL MARKETS CUTS TARGET PRICE TO $26 FROM $30
Reuters · 04/15 03:04
BUZZ-U.S. STOCKS ON THE MOVE-Netflix, Reddit, Stoke Therapeutics
The Dow Jones Industrial Average was up 0.72% on Wednesday. Merck & Co hit record high as FDA approves therapy for rare lung condition. Reddit Inc up 46% in fifth day of trading. Netflix, Reddit, Stoke Therapeutics are among the day's top stocks.
Reuters · 03/27 17:45
Lucid Diagnostics Inc reports results for the quarter ended in December - Earnings Summary
Lucid Diagnostics Inc reports results for the quarter ended in December. Revenue rose 828.6% to $1.04 million from a year ago. The company reported a quarterly loss of $10.83 million. Lucid Diagnostic Inc shares had fallen by 22.7% this quarter.
Reuters · 03/25 22:19
Lucid Diagnostics Inc <LUCD.OQ> expected to post a loss of 26 cents a share - Earnings Preview
Lucid Diagnostics Inc expected to post a loss of 26 cents a share. The company is expected to report a 840.9% increase in quarterly revenue to $1.054 million. The average analyst estimate for the company is for a quarterly loss of 26 cents per share.
Reuters · 03/22 20:45
PAVmed Inc <PAVM.OQ> expected to post a loss of $1.89 a share - Earnings Preview
PAVmed Inc expected to post a loss of $1.89 a share. The company is expected to report a 835.7% increase in quarterly revenue. The average analyst estimate for PAVmed's quarterly revenue is for a rise of 8.7%.
Reuters · 03/22 20:05
Lucid Diagnostics Inc <LUCD.OQ> expected to post a loss of 26 cents a share - Earnings Preview
Lucid Diagnostics Inc expected to post a loss of 26 cents a share. The company is expected to report a 840.9% increase in quarterly revenue to $1.054 million. LSEG's mean analyst estimate for the company is for a quarterly loss of 26 cents per share.
Reuters · 03/08 21:14
U.S. RESEARCH ROUNDUP- Cigna Group, Datadog, Landstar System
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Cigna Group, Datadog, Landstar System and Bluebird Bio among those. Analysts raise ratings and target prices on several companies on Monday. The companies include Axos Financial, GMS, Post Holdings and PTC.
Reuters · 12/11/2023 06:40
Lucid Diagnostics Inc reports results for the quarter ended in June - Earnings Summary
Reuters · 08/15/2023 13:31
Lucid Diagnostics Inc expected to post a loss of 32 cents a share - Earnings Preview
Reuters · 08/11/2023 16:42
BRIEF-Pavmed Inc - QTRLY Non-GAAP Adjusted Loss Per Share $0.10
Reuters · 05/16/2023 21:30
More
Webull provides a variety of real-time PAVMW stock news. You can receive the latest news about Pavmed through multiple platforms. This information may help you make smarter investment decisions.
About PAVMW
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.